Mark DePristo - designing antibodies with machine learning

We talk with Mark DePristo, founder and CEO of BigHat Biosciences, about building better antibody therapeutics using machine learning, overcoming the fear of failure, and the pros and cons of working in academia, for large companies like Google, and at a biotech start up.
The Bioinformatics CRO is a fully distributed contract research company that serves the computational biology needs of academic researchers and biotechnology companies, with a focus on genomics.
bioinformaticscro.com